A, CC (left) and MLO (right) low-energy images from pre-NAT CEM performed on...
A, CC (left) and MLO (right) low-energy images from pre-NAT CEM performed on 25th day of luteal phase show a 60-mm architectural distortion (line on CC) in the central portion of the right breast. B, CC (left) and MLO (right) recombined images from pre-NAT CEM show marked background parenchymal enhancement, hindering lesion evaluation; 90-mm non-mass regional enhancement (line) was described. C, Axial fat-saturated T1-weighted unenhanced MR image shows a 70-mm hypointense irregular mass (line) with not circumscribed margins in the central portion of right breast. D, Axial fat-saturated T1-weighted post-contrast MR images shows corresponding fast initial enhancement (line) with delayed plateau.

Credit: American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News • Contrast-enhanced mammography vs. MRI

Neoadjuvant therapy response in breast cancer

Contrast-enhanced mammography (CEM) may be a useful alternative test for neoadjuvant therapy (NAT) response assessment in patients with breast cancer who are unable to undergo MRI.

"After NAT for breast cancer, CEM and MRI yielded comparable assessments of lesion size (both slightly overestimated vs pathology) and RECIST categories, and no significant difference in specificity for pathologic complete response," wrote corresponding author Rubina Manuela Trimboli of IRCCS Humanitas Research Hospital in Milan, Italy. Noting that MRI had higher sensitivity for pathologic complete response, Trimboli wrote that "delayed CEM acquisition may help detect residual ductal carcinoma in situ (DCIS)."

Trimboli and the team's prospective study included 51 patients (mean age, 46 years) with biopsy-proven breast cancer from May 2015 to April 2018, who were candidates for NAT. Patients underwent both CEM and MRI before, during, and after NAT: pre-NAT, mid-NAT, and post-NAT, respectively. Post-NAT CEM included a 6-minute delayed acquisition. One breast radiologist with experience in CEM reviewed CEM examinations; one breast radiologist with experience in MRI reviewed MRI examinations.

Compared with pathology, post-NAT CEM, MRI, and delayed CEM systematically overestimated residual tumor size by 0.8 mm, 1.9 mm, and 1.2 mm, respectively. For detecting pathologic complete response by post-NAT imaging, sensitivity and specificity were 81% and 83% for CEM, 100% and 86% for MRI, and 81% and 89% for delayed CEM.

"While MRI remains the preferred test for NAT monitoring," the authors of the AJR article concluded, "the findings support CEM as a useful alternative when MRI is contraindicated or not tolerated."

Source: American Roentgen Ray Society

26.06.2022

Read all latest stories

Related articles

Photo

Article •

What´s new in breast MRI, tomosynthesis and elastography?

MRI: Although an area of constant debate, this is becoming a widely accepted clinical modality in Europe. However, researchers in The Netherlands have shown that performing pre-operative breast MRI…

Photo

News • Cancer imaging

MRI 2.0 lights up cancerous tissue

Synthetic correlated diffusion makes cancerous tissue glow in medical images could help doctors more accurately detect and track the progression of cancer over time.

Photo

News • Knowledge base for radiologists

Educational resources on dense breasts

In an effort to promote access to professional breast imaging knowledge, the European Society of Radiology (ESR) now links to educational materials from DenseBreast-info.org as a resource for its…

Related products

AB-CT – Advanced Breast-CT – nu:view

Mammo CT

AB-CT – Advanced Breast-CT – nu:view

AB-CT – Advanced Breast-CT GmbH
Fujifilm – AMULET Innovality

Tomosynthesis

Fujifilm – AMULET Innovality

FUJIFILM Europe GmbH
Fujifilm – AMULET Innovality Harmony

Tomosynthesis

Fujifilm – AMULET Innovality Harmony

FUJIFILM Europe GmbH
Subscribe to Newsletter